Immune Durability After VSV-EBOV Vaccination

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

95 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-11-30

Study Completion Date

2020-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective observational cohort study will follow the roughly 100 adults who received the VSV-ZEBOV vaccine in the Geneva phase 1 randomized controlled trial in 2014-2015 in order to determine their long-term (5-year) immune response to vaccination.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Surveillance of Vaccine-induced Immunity Against Ebola in Previously Vaccinated Health Care Workers

NCT05313139

Immune Response

UNKNOWN

Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure

NCT05959421

Ebola Vaccine

NOT_YET_RECRUITING PHASE3

VSV-ZEBOV Geneva Vaccine Trial

NCT02287480

Ebolavirus Disease

COMPLETED PHASE1/PHASE2

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults

NCT02485301

Virus Diseases

COMPLETED PHASE2

Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure

NCT02788227

Healthy Volunteers

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: During the Ebola epidemic of 2014-5, there was no proven therapy or prevention available beyond horizontal infection control measures. After the Canadian government donated 800 vials of the vaccine candidate VSV-EBOV to World Health Organization (WHO), the University Hospitals of Geneva agreed to perform a WHO-coordinated phase I/II double-blind, placebo-controlled randomized trial to assess the candidate's safety and immunogenicity healthy adult volunteers. The doses of 10 E7 pfu and 5 x 10 E7 pfu were tested in 35 and 16 volunteers, respectively, before a safety-driven study hold in late 2014. At trial resumption in early 2015, the remaining volunteers (n=51) received 3 x 10 E5 pfu. Thirteen volunteers received placebo. Among vaccinees, early immune responses were impressive, even at the lowest dose of 3 x 10 E5 pfu, and persisted well up to 6 months (last time point assessed). The trial successfully ended 12 months after injection. This prospective observational study will assess immune durability in this group of vaccinees at yearly time points up to five years post-vaccination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immune Response Vaccination Durability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

vaccinated with 5 x 10E7 pfu VSV-ZEBOV

Volunteers vaccinated in 2014 or 2015 with 5 x 10E7 pfu VSV-ZEBOV

No interventions assigned to this group

vaccinated with 10E7 pfu VSV-ZEBOV

Volunteers vaccinated in 2014 or 2015 with 10E7 pfu VSV-ZEBOV

No interventions assigned to this group

vaccinated with 3 x 10E5 pfu VSV-ZEBOV

Volunteers vaccinated in 2014 or 2015 with 3 x 10E5 pfu VSV-ZEBOV

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participated and was vaccinated with a single injection of VSV-EBOV at a dose of either 3 x 10E5 pfu, 10E7 pfu or 5 x 10E7 pfu in the Geneva phase I VSV-EBOV vaccine trial (NCT02287480).
* Able to provide written, informed consent for this observational study.